Inari Medical, Inc. (NASDAQ:NARI - Get Free Report) CFO Mitch C. Hill sold 6,000 shares of the firm's stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $40.96, for a total transaction of $245,760.00. Following the completion of the sale, the chief financial officer now owns 181,294 shares in the company, valued at approximately $7,425,802.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Inari Medical Trading Down 1.0 %
NARI opened at $38.70 on Thursday. Inari Medical, Inc. has a 1-year low of $38.35 and a 1-year high of $71.85. The firm's 50 day simple moving average is $47.67 and its two-hundred day simple moving average is $55.63.
Inari Medical (NASDAQ:NARI - Get Free Report) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.09). The firm had revenue of $132.10 million for the quarter, compared to the consensus estimate of $131.82 million. Inari Medical had a negative net margin of 0.33% and a positive return on equity of 1.23%. The firm's revenue for the quarter was up 22.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.11) earnings per share. As a group, sell-side analysts predict that Inari Medical, Inc. will post -0.39 earnings per share for the current fiscal year.
Analyst Ratings Changes
Elon’s New Device is About to Shock the World
From InvestorPlace | Ad
Using this device you see above…
Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in…
“The next step in human evolution.”
Click here to see the details because there’s a lot of money at stake.
NARI has been the topic of several research reports. Needham & Company LLC restated a "buy" rating and issued a $72.00 target price on shares of Inari Medical in a report on Wednesday, March 6th. Piper Sandler downgraded shares of Inari Medical from an "overweight" rating to a "neutral" rating and decreased their price target for the stock from $85.00 to $55.00 in a research report on Thursday, February 29th. Truist Financial decreased their price target on shares of Inari Medical from $61.00 to $52.00 and set a "hold" rating on the stock in a research report on Friday, March 22nd. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $75.00 price target on shares of Inari Medical in a research report on Friday, April 12th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $73.71.
Get Our Latest Stock Report on Inari Medical
Institutional Trading of Inari Medical
Several institutional investors and hedge funds have recently modified their holdings of NARI. Wellington Management Group LLP raised its position in shares of Inari Medical by 46.8% during the 1st quarter. Wellington Management Group LLP now owns 4,626,607 shares of the company's stock valued at $419,355,000 after purchasing an additional 1,475,313 shares during the period. Norges Bank bought a new stake in shares of Inari Medical during the 4th quarter valued at $73,924,000. Price T Rowe Associates Inc. MD increased its holdings in Inari Medical by 132.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,863,816 shares of the company's stock valued at $115,073,000 after acquiring an additional 1,060,839 shares during the last quarter. Morgan Stanley increased its holdings in Inari Medical by 400.9% in the 4th quarter. Morgan Stanley now owns 1,273,630 shares of the company's stock valued at $80,952,000 after acquiring an additional 1,019,378 shares during the last quarter. Finally, BlackRock Inc. increased its holdings in Inari Medical by 13.0% in the 2nd quarter. BlackRock Inc. now owns 6,385,806 shares of the company's stock valued at $371,271,000 after acquiring an additional 733,738 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors.
Inari Medical Company Profile
(
Get Free Report)
Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
